Lurbinectedin is a chemotherapy drug used to treat certain types of cancer. The duration of treatment with lurbinectedin can vary depending on several factors, including the type and stage of cancer being treated and the patient's overall health. According to DrugPatentWatch [1], the patent for lurbinectedin is set to expire in 2037, indicating that the drug is still under patent protection and is likely still being studied for optimal dosage and duration of treatment.

MedlinePlus [2] notes that lurbinectedin is typically administered by a healthcare provider in a hospital or clinic setting. The drug is given intravenously over a period of several hours. The frequency and duration of treatment may vary depending on the individual patient and the cancer being treated.

A recent study published in the Journal of Clinical Oncology [3] examined the efficacy and safety of lurbinectedin in treating small cell lung cancer. In this study, patients received lurbinectedin intravenously every three weeks until disease progression or unacceptable toxicity occurred. The median duration of treatment was 4.6 months, with some patients receiving treatment for up to 13 months.

In summary, the duration of lurbinectedin treatment can vary depending on several factors, including the type and stage of cancer being treated and the patient's overall health. The drug is typically administered intravenously in a hospital or clinic setting, and the frequency and duration of treatment may vary. Further research is needed to determine the optimal dosage and duration of treatment for lurbinectedin.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://medlineplus.gov/druginfo/meds/a620049.html
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/